BRSYF - GE's Bet On Neuronetics: Sell It At 8.32x Forward Sales
Neuronetics, Inc. (STIM) is now trading at 8.32x forward sales after delivering a decent quarterly release with 28.5% revenue growth. The valuation seems too high if we compare with other peers, thus it may be time to liquidate the position.
In this piece, there is further due diligence on what patients say about the treatment. There are beneficial as well as detrimental comments, but they all provide relevant information that could help in the investment decision-making of shareholders.
Source: 10-Q
Business And Due Diligence
Neuronetics, Inc. is a medical technology company commercializing the